Welcome to our dedicated page for Haemonetics Corporation news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Corporation stock.
Haemonetics Corporation (NYSE: HAE) is a global leader in blood management solutions, dedicated to improving patient care and reducing healthcare costs. The company offers a comprehensive portfolio of integrated devices, information management systems, and consulting services that address every facet of blood and plasma management. Haemonetics operates through three key segments: Plasma, Blood Center, and Hospital.
In the Plasma segment, Haemonetics focuses on providing innovative technologies for plasma collection and processing. The company's products help ensure a steady supply of high-quality plasma for the production of biopharmaceuticals and other therapeutic applications.
Within the Blood Center segment, Haemonetics offers advanced solutions for blood component collection and processing, aiding in the optimization of blood supply chains. Despite facing high competition in this segment, the company continues to innovate and enhance its product offerings.
The Hospital segment is a significant growth area for Haemonetics, providing essential tools for surgical suites and transfusion services. The company's technologies help prevent unnecessary blood transfusions and ensure the right blood product is used at the right time, improving patient outcomes.
Recently, Haemonetics has achieved several milestones, including the acquisition of Attune Medical, the manufacturer of the FDA-cleared ensoETM® esophageal cooling device. This acquisition strengthens Haemonetics' presence in the electrophysiology market and complements its vascular closure offerings.
Haemonetics also received 510(k) clearance from the U.S. FDA for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge, expanding its capabilities to serve fully heparinized patients in critical surgical procedures.
The company's financial performance remains robust, with a strong focus on revenue growth and strategic investments. Haemonetics continues to explore new markets and develop cutting-edge technologies to stay at the forefront of the healthcare industry.
To stay updated with the latest developments and financial results, Haemonetics regularly hosts investor calls and webcasts, providing transparency and insights into its ongoing projects and future plans.
Haemonetics Corporation (NYSE: HAE) announced that President and CEO Chris Simon will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2023, at 2:15 PM Pacific time. The live presentation will be available via audio webcast, accessible through Haemonetics' Investor Relations website. A replay will be available for 30 days after the event. Haemonetics focuses on innovative medical solutions aimed at improving patient care and reducing healthcare costs, specifically in blood and plasma component collection.
Haemonetics Corporation (NYSE: HAE) announced that its financial results for the second quarter of fiscal 2023, ending October 1, 2022, are now available on its Investor Relations website. A conference call and webcast will occur at 8:00 a.m. ET on November 7, 2022, to discuss these results. Interested parties can access the earnings release and supplemental information via provided links. A replay will be available for one year after the conference call. Haemonetics focuses on innovative medical products for improving patient care and reducing healthcare costs.
Haemonetics Corporation (NYSE: HAE) announced plans to release its second quarter fiscal year 2023 financial results on November 7, 2022, at 6:00 am ET. An accompanying conference call will be held at 8:00 am ET the same day for investors and analysts to discuss the results. Participants can access the call via teleconference or live webcast on Haemonetics' investor relations website. A replay of the call will be available for one year starting at 11:00 am ET on November 7, 2022.
Haemonetics Corporation (NYSE: HAE) has appointed Roy Galvin as the President of Global Plasma and Blood Center, effective October 10, 2022. Galvin brings over 25 years of experience from Medtronic, where he held various senior roles. He aims to drive transformational growth and enhance leadership in plasma collection and donor management solutions. His appointment comes at a crucial time as the company seeks to meet the rising global demand for plasma-derived therapies and improve productivity and cost efficiency in collection processes.
Haemonetics Corporation (NYSE: HAE) announced it has received CE mark certification for its VASCADE® vascular closure and VASCADE MVP® venous closure systems. This certification enables the company to launch these products in the European Union and other regions recognizing CE marking. The VASCADE system is tailored for small-bore femoral closure in various medical procedures, while VASCADE MVP is designed for mid-bore closures, particularly after cardiac ablation. Both systems aim to improve patient outcomes and hospital efficiency.
Haemonetics Corporation (NYSE: HAE) announced on August 29, 2022, a partnership with Epic, a major Electronic Health Record (EHR) provider, to integrate its SafeTrace Tx® blood bank information system into Epic's hospital network. SafeTrace Tx enhances transfusion management by ensuring patient safety and operational efficiency through comprehensive data management. This agreement aims to improve hospital transfusion processes amid ongoing staffing and blood supply challenges. Haemonetics continues to focus on innovative solutions to enhance patient care and optimize hospital operations.
Haemonetics Corporation (NYSE: HAE) announced that CEO Chris Simon will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 8:45 a.m. ET. Investors can access the live presentation via a webcast, with a replay available for 180 days post-event, starting at 12:00 p.m. ET. Haemonetics focuses on innovative medical products to enhance patient care and improve healthcare costs.
Haemonetics Corporation (NYSE: HAE) released its financial results for Q1 FY23, ending July 2, 2022. The results and additional analytical information are available on the company's Investor Relations website. A conference call is scheduled for August 10, 2022, at 8:00 a.m. EDT to discuss these results with investors and analysts. Participants can access the call via a teleconference link or live webcast. Earnings release and supplemental documents related to the quarter were also posted online for detailed review.
Haemonetics Corporation (NYSE: HAE) announced it will release its first quarter fiscal year 2023 financial results at 6:00 am EDT on August 10, 2022. A conference call for investors and analysts will follow at 8:00 am EDT on the same day. Participants can register to access the call and a live webcast will be available on the company's investor relations website. A replay of the call will be accessible for one year starting from 11:00 am EDT on August 10, 2022.
Haemonetics Corporation (NYSE: HAE) has officially launched operations at its new manufacturing Center of Excellence in Clinton, PA, covering 200,000 square feet. This facility enhances production capabilities for critical disposables and consumables across its Plasma and Hospital sectors. The site utilizes advanced technology and environmentally-friendly features, showcasing Haemonetics' commitment to operational excellence. With over 30 years in the Pittsburgh area, the company aims to improve patient outcomes while meeting growing demand.
FAQ
What is the current stock price of Haemonetics Corporation (HAE)?
What is the market cap of Haemonetics Corporation (HAE)?
What does Haemonetics Corporation specialize in?
What are the main segments of Haemonetics' business?
What recent acquisitions has Haemonetics made?
What is the TEG® 6s hemostasis analyzer system?
How does Haemonetics support its plasma segment?
What are the financial highlights of Haemonetics?
How does Haemonetics improve patient care?
What was the significance of the FDA clearance for Haemonetics?
What is Haemonetics' approach to innovation?
How can investors stay updated on Haemonetics' performance?
